Cargando…
Clinical significance of tissue inhibitor of metalloproteinase expression in gastric carcinoma.
Tissue inhibitor of metalloproteinase (TIMP) has been reported to inhibit tumour invasion through an inactivation of matrix metalloproteinase (MMP) both in vitro and in vivo. Among the TIMP family, TIMP-1 possesses not only proteinase inhibitory activity but also a growth-promoting function. However...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1997
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2227988/ https://www.ncbi.nlm.nih.gov/pubmed/9275032 |
_version_ | 1782149812561379328 |
---|---|
author | Mimori, K. Mori, M. Shiraishi, T. Fujie, T. Baba, K. Haraguchi, M. Abe, R. Ueo, H. Akiyoshi, T. |
author_facet | Mimori, K. Mori, M. Shiraishi, T. Fujie, T. Baba, K. Haraguchi, M. Abe, R. Ueo, H. Akiyoshi, T. |
author_sort | Mimori, K. |
collection | PubMed |
description | Tissue inhibitor of metalloproteinase (TIMP) has been reported to inhibit tumour invasion through an inactivation of matrix metalloproteinase (MMP) both in vitro and in vivo. Among the TIMP family, TIMP-1 possesses not only proteinase inhibitory activity but also a growth-promoting function. However, the significance of the expression of TIMP-1 in human gastric carcinoma tissue has yet to be clarified. In 50 examined cases of gastric carcinoma, 44 (88%) cases showed a higher expression of TIMP-1 mRNA in the biopsy samples from the tumour tissue (T) than in the biopsy samples from the corresponding normal tissue (N), as determined by semiquantitative reverse transcriptase-polymerase chain reaction (RT-PCR). In a multivariate analysis, the T/N ratio of TIMP-1 mRNA was found to be an independent factor influencing the depth of tumour invasion and was the second most important factor in determining the prognosis of patients. As RT-PCR assay can be performed on biopsy specimens obtained before surgery, an evaluation of the TIMP-1 expression in biopsy specimens by RT-PCR may thus provide useful preoperative information on tumour aggressiveness. IMAGES: |
format | Text |
id | pubmed-2227988 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1997 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-22279882009-09-10 Clinical significance of tissue inhibitor of metalloproteinase expression in gastric carcinoma. Mimori, K. Mori, M. Shiraishi, T. Fujie, T. Baba, K. Haraguchi, M. Abe, R. Ueo, H. Akiyoshi, T. Br J Cancer Research Article Tissue inhibitor of metalloproteinase (TIMP) has been reported to inhibit tumour invasion through an inactivation of matrix metalloproteinase (MMP) both in vitro and in vivo. Among the TIMP family, TIMP-1 possesses not only proteinase inhibitory activity but also a growth-promoting function. However, the significance of the expression of TIMP-1 in human gastric carcinoma tissue has yet to be clarified. In 50 examined cases of gastric carcinoma, 44 (88%) cases showed a higher expression of TIMP-1 mRNA in the biopsy samples from the tumour tissue (T) than in the biopsy samples from the corresponding normal tissue (N), as determined by semiquantitative reverse transcriptase-polymerase chain reaction (RT-PCR). In a multivariate analysis, the T/N ratio of TIMP-1 mRNA was found to be an independent factor influencing the depth of tumour invasion and was the second most important factor in determining the prognosis of patients. As RT-PCR assay can be performed on biopsy specimens obtained before surgery, an evaluation of the TIMP-1 expression in biopsy specimens by RT-PCR may thus provide useful preoperative information on tumour aggressiveness. IMAGES: Nature Publishing Group 1997 /pmc/articles/PMC2227988/ /pubmed/9275032 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Mimori, K. Mori, M. Shiraishi, T. Fujie, T. Baba, K. Haraguchi, M. Abe, R. Ueo, H. Akiyoshi, T. Clinical significance of tissue inhibitor of metalloproteinase expression in gastric carcinoma. |
title | Clinical significance of tissue inhibitor of metalloproteinase expression in gastric carcinoma. |
title_full | Clinical significance of tissue inhibitor of metalloproteinase expression in gastric carcinoma. |
title_fullStr | Clinical significance of tissue inhibitor of metalloproteinase expression in gastric carcinoma. |
title_full_unstemmed | Clinical significance of tissue inhibitor of metalloproteinase expression in gastric carcinoma. |
title_short | Clinical significance of tissue inhibitor of metalloproteinase expression in gastric carcinoma. |
title_sort | clinical significance of tissue inhibitor of metalloproteinase expression in gastric carcinoma. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2227988/ https://www.ncbi.nlm.nih.gov/pubmed/9275032 |
work_keys_str_mv | AT mimorik clinicalsignificanceoftissueinhibitorofmetalloproteinaseexpressioningastriccarcinoma AT morim clinicalsignificanceoftissueinhibitorofmetalloproteinaseexpressioningastriccarcinoma AT shiraishit clinicalsignificanceoftissueinhibitorofmetalloproteinaseexpressioningastriccarcinoma AT fujiet clinicalsignificanceoftissueinhibitorofmetalloproteinaseexpressioningastriccarcinoma AT babak clinicalsignificanceoftissueinhibitorofmetalloproteinaseexpressioningastriccarcinoma AT haraguchim clinicalsignificanceoftissueinhibitorofmetalloproteinaseexpressioningastriccarcinoma AT aber clinicalsignificanceoftissueinhibitorofmetalloproteinaseexpressioningastriccarcinoma AT ueoh clinicalsignificanceoftissueinhibitorofmetalloproteinaseexpressioningastriccarcinoma AT akiyoshit clinicalsignificanceoftissueinhibitorofmetalloproteinaseexpressioningastriccarcinoma |